IDO-IN-7

IDO-IN-7 (NLG-919 analogue) 是 IDO1 抑制剂,IC50=38 nM。

CAS号

1402836-58-1

分子式

C18H22N2O

主要靶点

Indoleamine 2,3-Dioxygenase (IDO)

仅限科研使用

Cat No : CM04703

Print datasheet

Synonyms

GDC-0919|Navoximod|NLG919|NLG-919 analogue



产品信息

IDO-IN-7 (NLG-919 analogue) is a potent IDO (indoleamine-(2, 3)-dioxygenase) pathway inhibitor.

CAS号 1402836-58-1
分子式 C18H22N2O
主要靶点 Indoleamine 2,3-Dioxygenase (IDO)
主要通路 代谢
分子量 282.38
纯度 99.79%, 此纯度可做参考,具体纯度与批次有关系,可咨询客服
储存条件 Powder: -20°C for 3 years | In solvent: -80°C for 1 year
别名 GDC-0919|Navoximod|NLG919|NLG-919 analogue

靶点活性

IDO:75 nM(EC50)

体内活性

NLG919能够显著阻断IDO诱导的T细胞抑制作用,恢复的T细胞反应(ED50=80 nM)。 在来自肿瘤淋巴结的表达IDO的小鼠DC细胞(ED50=120 nM),NLG919消除IDO诱导的抗原特异性T细胞(OT-1)抑制。

体外活性

在含B16F10瘤的小鼠中,NLG919明显增强了pmel-1静息细胞对同源hgp100肽和CpG-1826的抗肿瘤反应.

溶解度

Ethanol:26 mg/mL(92.1 mM),DMSO:15 mg/mL (53.11 mM),H2O:<1 mg/mL

参考文献

1.AACR Meeting, Poster 491, 2013.
2.Zhou Y, Lu X, Du C, et al. Novel BuChE-IDO1 inhibitors from sertaconazole: Virtual screening, chemical optimization and molecular modeling studies[J]. Bioorganic & Medicinal Chemistry Letters. 2021, 34: 127756.
3.Nguyen D J M, Theodoropoulos G, Li Y Y, et al. Targeting the kynurenine pathway for the treatment of cisplatin resistant lung cancer[J]. Molecular Cancer Research. 2019: molcanres. 0239.2019.
4.Nguyen D J M, Theodoropoulos G, Li Y Y, et al. Targeting the kynurenine pathway for the treatment of cisplatin-resistant lung cancer[J]. Molecular Cancer Research. 2020, 18(1): 105-117.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
=
×
×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
×
=
×
C1   V1   C2   V2